Search

everythinglearnresearchcommunity

for

Search:↓

The combined treatment effectively managed severe skin issues in Olmsted syndrome.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

Tofacitinib helped regrow hair in most patients with severe hair loss.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Suppressing ODC activity reduces tumor growth in hair follicles.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Pegvaliase effectively reduces blood phenylalanine levels in most PKU patients, but requires personalized plans and good communication to manage side effects.

Cetuximab can cause eyelash growth, which is rare but manageable.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.